Compare FIX & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIX | INSM |
|---|---|---|
| Founded | 1917 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.9B | 35.2B |
| IPO Year | 1997 | 2000 |
| Metric | FIX | INSM |
|---|---|---|
| Price | $1,390.06 | $146.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 23 |
| Target Price | ★ $1,378.67 | $188.73 |
| AVG Volume (30 Days) | 419.1K | ★ 2.1M |
| Earning Date | 05-22-2026 | 05-21-2026 |
| Dividend Yield | ★ 0.20% | N/A |
| EPS Growth | ★ 97.81 | N/A |
| EPS | ★ 28.88 | N/A |
| Revenue | ★ $9,101,641,000.00 | N/A |
| Revenue This Year | $12.90 | $168.46 |
| Revenue Next Year | $10.53 | $65.97 |
| P/E Ratio | $48.08 | ★ N/A |
| Revenue Growth | ★ 29.52 | N/A |
| 52 Week Low | $276.44 | $60.40 |
| 52 Week High | $1,500.00 | $212.75 |
| Indicator | FIX | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 59.32 | 38.28 |
| Support Level | $791.28 | $139.81 |
| Resistance Level | N/A | $149.08 |
| Average True Range (ATR) | 69.29 | 6.88 |
| MACD | -3.44 | -0.03 |
| Stochastic Oscillator | 50.05 | 11.78 |
Comfort Systems USA Inc provides comprehensive mechanical contracting services, including heating, ventilation, & air conditioning, or HVAC; plumbing; piping & controls; construction; and other electrical components. Projects are mainly for commercial, industrial, & institutional buildings, & tend to be geared toward HVAC. Revenue is roughly split between installation services for newly constructed facilities & maintenance services for existing buildings. The company installs & repairs products and systems throughout the United States. It operates in two segments, Mechanical services & Electrical services, the majority is from the Mechanical services segment.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.